Sandoz
This article was originally published in The Tan Sheet
Executive Summary
Plans streamlining/restructuring measures once an analysis of the firm's operations by "functional management teams" is completed at the end of the first quarter of 1994. Among the factors Sandoz said it will take into account in devising a restructuring plan include an increased emphasis on Rx-to-OTC switches and the pending health care proposals. Sandoz said it is currently examining its product portfolio with an eye to potential OTC switches. The firm expects that "fewer individuals will be affected at Sandoz compared to recent personnel announcements made by other pharmaceutical companies." Upjohn, Pfizer and Lederle are among companies that have recently announced work force reductions ("The Tan Sheet" Nov. 1, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning